Reversible increase in serum lithium conc & toxicity. Increased antihypertensive effect w/ baclofen. Increased worsening of renal function w/ NSAIDs. Increased antihypertensive effect & orthostatic hypotension w/ imipramine-like antidepressants (tricyclics) & neuroleptics. Perindopril: Higher frequency of adverse events w/ angiotensin II receptor blockers, aliskiren & estramustine. Increased risk of hyperkalemia w/ aliskiren, K salts, K-sparing diuretics, ACEIs, AIIAs, NSAIDs, heparins, immunosuppressant agents eg, ciclosporin or tacrolimus, trimethoprim. Extracorporeal treatments. Increased risk of angioedema w/ racecadotril, mTOR inhibitors (eg, sirolimus, everolimus, temsirolimus), sacubitril/valsartan, gliptins (linagliptin, saxagliptin, sitagliptin,
vildagliptin. Increased blood-glucose lowering effect w/ antidiabetic agents (insulin, oral hypoglycemic agents). May increase hypotensive effects w/ antihypertensive agents, vasodilators, anesth. Increased risk for leucopenia w/ allopurinol, cytostatic or immunosuppressive agents,
systemic corticosteroids or procainamide. Reduced antihypertensive effects w/ ACEIs. Nitritoid reactions w/ gold. Indapamide: Induce Torsades de pointes w/ class IA antiarrhythmic agents (quinidine, hydroquinidine, disopyramide), class III antiarrhythmic agents (amiodarone, dofetilide, ibutilide, bretylium, sotalol), some neuroleptics (chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine), benzamides (amisulpride, sulpiride, sultopride, tiapride), butyrophenones (droperidol, haloperidol), other neuroleptics (pimozide), other substances such as bepridil, cisapride, diphemanil, IV erythromycin, halofantrine, mizolastine, moxifloxacin, pentamidine, sparfloxacin, IV vincamine, methadone, astemizole, terfenadine. Increased risk of low K levels w/ amphotericin B (IV route), glucocorticoids, mineralocorticoids (systemic route), tetracosactide, stimulant laxatives, digitalis prep. Increased incidence of hypersensitivity reactions to allopurinol. Lactic acidosis w/ metformin. Increased risk of acute renal insufficiency w/ iodinated contrast media. Increased levels w/ Ca salts. Increased creatinine levels w/ ciclosporin & tacrolimus. Reduced antihypertensive effect w/ corticosteroids, tetracosactide (systemic route).